THU0177 ABT-494 pharmacokinetics following administration of the once-daily extended-release tablet formulation being utilized in the ongoing rheumatoid arthritis phase 3 trials
Keyword(s):
Phase 3
◽
2017 ◽
Vol 34
(6)
◽
pp. 1187-1192
◽
2003 ◽
Vol 43
(10)
◽
pp. 1149-1157
◽
Keyword(s):
2013 ◽
Vol 2
(1)
◽
pp. 25-32
◽
2017 ◽
Vol 34
(7)
◽
pp. 1527-1533
◽
2004 ◽
Vol 58
(3)
◽
pp. 607-614
◽
Keyword(s):
2016 ◽
Vol 38
(2)
◽
pp. 302-314
◽
Keyword(s):
2010 ◽
Vol 50
(5)
◽
pp. 544-553
◽